Search

Omadacycline

Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent

Cobicistat

More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1

Thyroid, porcine

[A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.

Vilanterol

[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.

Chloric acid

Indocyanine green acid form

The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide,

Chlorambucil

Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

Ferric derisomaltose

The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide.

Defactinib

[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in

Benzethonium

It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. … It is shown to be effective in mediating its antimicrobial action against bacteria, fungi, mold and viruses.